quinazolines has been researched along with Cancer of Cecum in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Braun, M; Cassidy, J; Chau, I; Falk, S; Finnigan, H; Ford, H; Harrison, M; Hickish, T; Iveson, T; Jones, H; Lee, C; Macpherson, IR; Potter, V; Propper, D | 1 |
Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
Faessel, HM; Greco, WR; Rustum, YM; Slocum, HK | 1 |
1 trial(s) available for quinazolines and Cancer of Cecum
Article | Year |
---|---|
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cecal Neoplasms; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2014 |
2 other study(ies) available for quinazolines and Cancer of Cecum
Article | Year |
---|---|
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Cell Division; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Folic Acid; Glutamates; Hematinics; Humans; Hydroxymethyl and Formyl Transferases; Hypoxanthine; Ileal Neoplasms; Peptide Synthases; Phosphoribosylglycinamide Formyltransferase; Pyrimidines; Quinazolines; Thiophenes; Thymidine; Thymidylate Synthase; Trimetrexate; Tumor Cells, Cultured | 2003 |